Viridian Therapeutics, Inc. (NASDAQ: VRDN) reported Q2 EPS of ($1.27), $0.01 worse than the analyst estimate of ($1.26). Revenue for the quarter came in at $70 thousand versus the consensus estimate of $254 thousand.

For earnings history and earnings-related data on Viridian Therapeutics, Inc. (VRDN) click here.